Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization, G1 vs. G2 -74% Improvement Relative Risk Case, G1 vs. G2 79% Case, G1 vs. G2 (b) 59% Case, G1 vs. G2 (c) 79% ICU admission, G3 vs. G4 57% Hospitalization, G3 vs. G4 -350% Case, G3 vs. G4 -15% Case, G3 vs. G4 (b) 32% Case, G3 vs. G4 (c) 22% c19vitamind.com Romero-Ibarguengoitia et al. NCT04810949 Vitamin D RCT Prophylaxis Favors vitamin D Favors diet/sun
Romero-Ibarguengoitia, 112 patient vitamin D prophylaxis RCT: 79% fewer cases [p=0.008] https://c19p.org/romeroibarguengoitia
copied to clipboard
Effect of Vitamin D3 supplementation vs. dietary-hygienic measures on SARS-COV-2 infection rates in hospital workers with 25-hydroxyvitamin D3 [25(OH)D3] levels >20 ng/mL
Romero-Ibarguengoitia et al., medRxiv, doi:10.1101/2022.07.12.22277450 (Preprint), NCT04810949 (history)
15 Jul 2022    Source   PDF   Share   Tweet
RCT healthcare workers with vitamin D levels between 20-100 ng/mL, 43 treated with vitamin D 52,000 IU monthly, and 42 with dietary-hygienic measures, which were also focused on increasing vitamin D, including sun exposure for at least 10 minutes per day between 10:00-18:00, and consuming foods rich in vitamin D. There was significantly lower risk of COVID-19 with supplementation vs. diet/sun. Authors also report on patients with levels <20 ng/mL where treatment was recommended for all patients, however many patients declined treatment. In these non-randomized patients, lower risk was seen at 4 months with vitamin D supplementation, however there was no significant difference at 6 months.
Interpretation of the results is difficult because all groups had intervention aimed at increasing vitamin D. Supplemented patients showed greater improvement in levels, however dietary/sun patients could have a therapeutic advantage due to regular versus monthly consumption, and due to other benefits of the dietary/sun intervention. Authors indicate they asked patients monthly about consumption of food with vitamin D, however no results are provided.
risk of hospitalization, 73.7% higher, RR 1.74, p = 1.00, treatment 2 of 38 (5.3%), control 1 of 33 (3.0%), G1 vs. G2.
risk of case, 79.0% lower, HR 0.21, p = 0.008, treatment 5 of 38 (13.2%), control 13 of 33 (39.4%), NNT 3.8, 6 months, Cox proportional hazards, G1 vs. G2.
risk of case, 59.1% lower, RR 0.41, p = 0.04, treatment 6 of 43 (14.0%), control 14 of 41 (34.1%), NNT 5.0, 4 months, G1 vs. G2.
risk of case, 79.1% lower, RR 0.21, p = 0.003, treatment 3 of 43 (7.0%), control 14 of 42 (33.3%), NNT 3.8, 3 months, G1 vs. G2.
risk of ICU admission, 57.1% lower, RR 0.43, p = 1.00, treatment 0 of 24 (0.0%), control 1 of 72 (1.4%), NNT 72, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), G3 vs. G4.
risk of hospitalization, 350.0% higher, RR 4.50, p = 0.10, treatment 3 of 24 (12.5%), control 2 of 72 (2.8%), G3 vs. G4.
risk of case, 15.0% higher, HR 1.15, p = 0.72, treatment 9 of 24 (37.5%), control 29 of 72 (40.3%), 6 months, Cox proportional hazards, G3 vs. G4.
risk of case, 32.1% lower, RR 0.68, p = 0.35, treatment 7 of 27 (25.9%), control 29 of 76 (38.2%), NNT 8.2, 4 months, G3 vs. G4.
risk of case, 22.2% lower, RR 0.78, p = 0.64, treatment 7 of 28 (25.0%), control 27 of 84 (32.1%), NNT 14, 3 months, G3 vs. G4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Romero-Ibarguengoitia et al., 15 Jul 2022, Randomized Controlled Trial, Mexico, preprint, mean age 44.4, 5 authors, study period May 2020 - August 2020, dosage 52,000IU single dose, monthly, this trial compares with another treatment - results may be better when compared to placebo, trial NCT04810949 (history).
Contact: drgzzcantu@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit